Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

GSK and Vir Biotechnology seek EUA for COVID-19 monoclonal antibody

By Brian Buntz | March 26, 2021

GSK–VirGlaxoSmithKline and Vir Biotechnology have filed for emergency use authorization (EUA) for VIR-7831 (GSK4182136), a dual-action SARS-CoV-2 monoclonal antibody.

VIR-7831 is designed to stop SARS-CoV-2 viral entry into cells and accelerate the clearing of infected cells.

VIR-7831 would have a similar indication to other monoclonal antibodies that have won an EUA. It is intended for patients 12 or older who weigh at least 40 kg who have a high risk of hospitalization or death from COVID-19.

One notable example of a monoclonal antibody that has won such an EUA from the FDA is Lilly’s bamlanivimab, which is intended to be used soon after a positive COVID-19 test result is obtained but is contraindicated for patients who are hospitalized COVID-19 infections.

Compared with bamlanivimab, VIR-7831 may offer more resistance to SARS-CoV-2 variants based on preclinical data and a preprint study published in BioRxiv.

The U.S. government recently stopped using bamlanivimab as a monotherapy over concerns that several viral variants could resist the treatment.

In a placebo-controlled Phase 3 study, VIR-7831 appeared to reduce the risk of hospitalization or death from COVID-19 by 85%

GSK and Vir are also seeking to make the antibody available in Europe.


Filed Under: Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, Eli Lilly, GlaxoSmithKline, GSK, Lilly, SARS-CoV-2, SARS-CoV-2 variants, Vir Biotechnology, VIR-7831
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Pfizer-BioNTech
FDA allows booster dose Pfizer-BioNTech COVID-19 vaccine in children 5 to 11
AstraZeneca RQ Biotechnology
AstraZeneca paying up to $157M for broad-spectrum monoclonal antibodies against COVID
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Olumiant
FDA approves Olumiant for treating some hospitalized COVID-19 patients

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50